Search research articles
Contact Us
Filters
Showing results (41-50 of 46) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 46 results.
Neuropharmacology
|
August 8, 2001
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety
M D Wood, C Reavill, B Trail, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
July 25, 2000
Implementation of a large-scale ENU mutagenesis program: towards increasing the mouse mutant resource
P M Nolan, J Peters, L Vizor, et al.
Journal of Medicinal Chemistry
|
May 5, 2000
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat
G Stemp, T Ashmeade, C L Branch, et al.
Molecular and Cellular Neurosciences
|
December 31, 2003
LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease
S M Harrison, C Reavill, G Brown, et al.
Molecular and Cellular Neurosciences
|
June 21, 2001
Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice
H M Prosser, C H Gill, W D Hirst, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 17, 2000
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A
C Reavill, S G Taylor, M D Wood, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 46) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 46 results.
Neuropharmacology
|
August 8, 2001
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety
M D Wood, C Reavill, B Trail, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
July 25, 2000
Implementation of a large-scale ENU mutagenesis program: towards increasing the mouse mutant resource
P M Nolan, J Peters, L Vizor, et al.
Journal of Medicinal Chemistry
|
May 5, 2000
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat
G Stemp, T Ashmeade, C L Branch, et al.
Molecular and Cellular Neurosciences
|
December 31, 2003
LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease
S M Harrison, C Reavill, G Brown, et al.
Molecular and Cellular Neurosciences
|
June 21, 2001
Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice
H M Prosser, C H Gill, W D Hirst, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 17, 2000
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A
C Reavill, S G Taylor, M D Wood, et al.
Page
of 5